PMID- 15006729
OWN - NLM
STAT- MEDLINE
DCOM- 20040713
LR  - 20191026
IS  - 1471-2598 (Print)
IS  - 1471-2598 (Linking)
VI  - 4
IP  - 3
DP  - 2004 Mar
TI  - Novel peptide-based HIV-1 immunotherapy.
PG  - 349-61
AB  - Therapeutic immunisation of human immunodeficiency virus type 1-infected 
      individuals should be actively pursued in the first instance to augment highly 
      active antiretroviral therapy regimens. Peptide-based immunotherapeutic 
      strategies offer considerable advantages over conventional approaches, 
      particularly regarding safety. Peptide design itself is becoming increasingly 
      sophisticated, with the rapid evolution of bioinformatics tools that can analyse 
      not only T cell epitopes, but also their potential for successful presentation on 
      diverse human leukocyte antigen (HLA) class I or II following intracellular 
      processing by antigen-presenting cells (APCs). By targeting conserved viral 
      domains, peptides acquire improved reactivity to diverse viral strains. Dendritic 
      cells represent a powerful route of administration, as they are the most potent 
      APCs and can present exogenous peptides on both HLA class I and II through the 
      process of cross-presentation. In this way, soluble peptides can thereby 
      stimulate both CD4+ and CD8+ T cells.
FAU - Sommerfelt, Maja A
AU  - Sommerfelt MA
AD  - Bionor Immuno AS, Stromdaljordet 4, PO Box 1823 Gulset, NO-3703 Skien, Norway. 
      Maja.sommerfelt@bionorimmuno.com
FAU - Nyhus, Jorgen
AU  - Nyhus J
FAU - Sorensen, Birger
AU  - Sorensen B
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Peptides)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Drug Design
MH  - HIV Infections/*therapy
MH  - *HIV-1
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Peptides/immunology/*therapeutic use
RF  - 118
EDAT- 2004/03/10 05:00
MHDA- 2004/07/14 05:00
CRDT- 2004/03/10 05:00
PHST- 2004/03/10 05:00 [pubmed]
PHST- 2004/07/14 05:00 [medline]
PHST- 2004/03/10 05:00 [entrez]
AID - 10.1517/14712598.4.3.349 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2004 Mar;4(3):349-61. doi: 10.1517/14712598.4.3.349.